All the data evoked the interest to further study whether FGF21 could protect hepatocytes via negative feedback to the hepatocyte-derived IL-17A production, and thereby prevent NASH-HCC. The gene discussed is IL17A; the disease is metabolic dysfunction-associated steatohepatitis.